A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma

MLA

Michael J. Pishvaian, et al. “A Phase II Multicenter Study Evaluating Combination Immunotherapy with Pembrolizumab and Peginterferon Alfa-2b for Advanced Cholangiocarcinoma.” Journal of Clinical Oncology, vol. 35, Feb. 2017, p. TPS507. EBSCOhost, https://doi.org/10.1200/jco.2017.35.4_suppl.tps507.

APA

Michael J. Pishvaian, Brandon G. Smaglo, John L. Marshall, Mohamed E. Salem, Davendra Sohal, Aiwu Ruth He, Renuka Iyer, Karen Dorsch-Vogel, Michael A. Morse, & Hongkun Wang. (2017). A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma. Journal of Clinical Oncology, 35, TPS507. https://doi.org/10.1200/jco.2017.35.4_suppl.tps507

Chicago

Michael J. Pishvaian, Brandon G. Smaglo, John L. Marshall, Mohamed E. Salem, Davendra Sohal, Aiwu Ruth He, Renuka Iyer, Karen Dorsch-Vogel, Michael A. Morse, and Hongkun Wang. 2017. “A Phase II Multicenter Study Evaluating Combination Immunotherapy with Pembrolizumab and Peginterferon Alfa-2b for Advanced Cholangiocarcinoma.” Journal of Clinical Oncology 35 (February): TPS507. doi:10.1200/jco.2017.35.4_suppl.tps507.